804 related articles for article (PubMed ID: 8895688)
1. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
2. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
[TBL] [Abstract][Full Text] [Related]
3. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
4. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
Larson RA; Le Beau MM
Chem Biol Interact; 2005 May; 153-154():187-95. PubMed ID: 15935816
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
[TBL] [Abstract][Full Text] [Related]
6. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
Bloomfield CD; Shuma C; Regal L; Philip PP; Hossfeld DK; Hagemeijer AM; Garson OM; Peterson BA; Sakurai M; Alimena G; Berger R; Rowley JD; Ruutu T; Mitelman F; Dewald GW; Swansbury J
Cancer; 1997 Dec; 80(11 Suppl):2191-8. PubMed ID: 9395033
[TBL] [Abstract][Full Text] [Related]
10. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Larson RA
Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
[TBL] [Abstract][Full Text] [Related]
11. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
12. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
13. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
14. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
Stasi R; Venditti A; Del Poeta G; Aronica G; Dentamaro T; Cecconi M; Stipa E; Scimò MT; Masi M; Amadori S
Cancer; 1996 Jun; 77(12):2476-88. PubMed ID: 8640696
[TBL] [Abstract][Full Text] [Related]
15. Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression.
Cascavilla N; Musto P; D'Arena G; Ladogana S; Matera R; Carotenuto M
Haematologica; 1997; 82(1):31-7. PubMed ID: 9107079
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
[TBL] [Abstract][Full Text] [Related]
17. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
van Rhenen A; Feller N; Kelder A; Westra AH; Rombouts E; Zweegman S; van der Pol MA; Waisfisz Q; Ossenkoppele GJ; Schuurhuis GJ
Clin Cancer Res; 2005 Sep; 11(18):6520-7. PubMed ID: 16166428
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
19. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
